|
JO3474B1
(ar)
|
2014-08-29 |
2020-07-05 |
Amgen Inc |
مشتقات تيتراهيدرونافثالين التي تثبط بروتين mcl-1
|
|
WO2017147410A1
(en)
*
|
2016-02-25 |
2017-08-31 |
Amgen Inc. |
Compounds that inhibit mcl-1 protein
|
|
CN109790143A
(zh)
|
2016-05-10 |
2019-05-21 |
C4医药公司 |
用于靶蛋白降解的胺连接的c3-戊二酰亚胺降解决定子体
|
|
WO2017197036A1
(en)
|
2016-05-10 |
2017-11-16 |
C4 Therapeutics, Inc. |
Spirocyclic degronimers for target protein degradation
|
|
WO2017197046A1
(en)
|
2016-05-10 |
2017-11-16 |
C4 Therapeutics, Inc. |
C3-carbon linked glutarimide degronimers for target protein degradation
|
|
EP3454856B1
(en)
|
2016-05-10 |
2024-09-11 |
C4 Therapeutics, Inc. |
Heterocyclic degronimers for target protein degradation
|
|
AU2017300738A1
(en)
|
2016-07-22 |
2019-02-07 |
Les Laboratoires Servier |
Combination of a BCL-2 inhibitor and a MCL-1 inhibitor, uses and pharmaceutical compositions thereof
|
|
JP6453507B2
(ja)
|
2017-03-30 |
2019-01-16 |
アムジエン・インコーポレーテツド |
Ｍｃｌ−１タンパク質を阻害する化合物
|
|
EP3641762A4
(en)
|
2017-06-20 |
2021-03-10 |
C4 Therapeutics, Inc. |
N / O-LINKED DEGRONES AND DEGRONIMERS FOR PROTEIN DEGRADATION
|
|
SG10202106345VA
(en)
*
|
2017-08-15 |
2021-07-29 |
Abbvie Inc |
Macrocyclic mcl-1 inhibitors and methods of use
|
|
US20200239494A1
(en)
*
|
2017-08-15 |
2020-07-30 |
Abbvie Inc. |
Macrocyclic mcl-1 inhibitors and methods of use
|
|
EP3668878B1
(en)
|
2017-08-18 |
2025-05-21 |
Amgen Inc. |
Compounds that inhibit mcl-1 protein
|
|
US11279712B2
(en)
|
2017-08-29 |
2022-03-22 |
Amgen Inc. |
Macrocyclic compounds that inhibit MCL-1 protein
|
|
WO2019173181A1
(en)
*
|
2018-03-05 |
2019-09-12 |
Amgen Inc. |
Alpha-hydroxy phenylacetic acid pharmacophore or bioisostere mcl-1 protein antagonists
|
|
EP4029868A1
(en)
|
2018-05-14 |
2022-07-20 |
Gilead Sciences, Inc. |
Mcl-1 inhibitors
|
|
BR112021008796A2
(pt)
*
|
2018-11-09 |
2021-08-03 |
Prelude Therapeutics, Incorporated |
derivados de espiro-sulfonamida como inibidores de proteína de leucemia-1 de células mieloides (mcl-1)
|
|
EP3897631A4
(en)
|
2018-12-20 |
2022-11-23 |
C4 Therapeutics, Inc. |
TARGETED PROTEIN BREAKDOWN
|
|
TWI745836B
(zh)
*
|
2019-01-18 |
2021-11-11 |
大陸商蘇州亞盛藥業有限公司 |
作為mcl-1抑製劑的大螺環醚
|
|
GEAP202515825A
(en)
|
2019-05-20 |
2025-07-25 |
Servier Lab |
Mcl-1 inhibitor antibody-drug conjugates and methods of use
|
|
US11453681B2
(en)
|
2019-05-23 |
2022-09-27 |
Gilead Sciences, Inc. |
Substituted eneoxindoles and uses thereof
|
|
MA56505A
(fr)
*
|
2019-06-21 |
2022-04-27 |
Janssen Pharmaceutica Nv |
Inhibiteurs macrocycliques de mcl-1
|
|
KR102776925B1
(ko)
|
2019-06-25 |
2025-03-11 |
길리애드 사이언시즈, 인코포레이티드 |
Flt3l-fc 융합 단백질 및 사용 방법
|
|
JP7573591B2
(ja)
|
2019-07-09 |
2024-10-25 |
ヤンセン ファーマシューティカ エヌ．ベー． |
Ｍｃｌ－１阻害剤としての大環状スピロ環誘導体
|
|
EP3771469A1
(en)
*
|
2019-07-30 |
2021-02-03 |
Amgen, Inc |
Formulations and dosages for administering a compound that inhibits mcl1 protein
|
|
WO2021047616A1
(zh)
*
|
2019-09-12 |
2021-03-18 |
苏州亚盛药业有限公司 |
氧氮杂环庚烷类螺环化合物、中间体及其制备方法
|
|
EP4045083B1
(en)
|
2019-10-18 |
2024-01-10 |
Forty Seven, Inc. |
Combination therapies for treating myelodysplastic syndromes and acute myeloid leukemia
|
|
CA3153636A1
(en)
|
2019-10-31 |
2021-05-06 |
Forty Seven, Inc. |
Anti-cd47 and anti-cd20 based treatment of blood cancer
|
|
CN114901366A
(zh)
*
|
2019-11-04 |
2022-08-12 |
锐新医药公司 |
Ras抑制剂
|
|
WO2021091982A1
(en)
|
2019-11-04 |
2021-05-14 |
Revolution Medicines, Inc. |
Ras inhibitors
|
|
TWI778443B
(zh)
|
2019-11-12 |
2022-09-21 |
美商基利科學股份有限公司 |
Mcl1抑制劑
|
|
CN120098025A
(zh)
|
2019-11-26 |
2025-06-06 |
吉利德科学公司 |
用于制备mcl1抑制剂的方法和中间体
|
|
PH12022551441A1
(en)
|
2019-12-24 |
2023-11-20 |
Carna Biosciences Inc |
Diacylglycerol kinase modulating compounds
|
|
MX2022009947A
(es)
|
2020-02-14 |
2022-11-07 |
Jounce Therapeutics Inc |
Anticuerpos y proteinas de fusion que se unen a ccr8 y usos de estos.
|
|
EP4107161A1
(en)
*
|
2020-02-21 |
2022-12-28 |
Janssen Pharmaceutica NV |
Macrocyclic indole derivatives as inhibitors of mcl-1
|
|
JP2021161114A
(ja)
*
|
2020-03-31 |
2021-10-11 |
アムジエン・インコーポレーテツド |
Ｍｃｌ−１化合物のメチル化
|
|
US20230212191A1
(en)
*
|
2020-04-16 |
2023-07-06 |
Prelude Therapeutics, Incorporated |
Spiro-sulfonimidamide derivatives as inhibitors of myeloid cell leukemia-1 (mcl-1) protein
|
|
EP4143194A1
(en)
|
2020-05-01 |
2023-03-08 |
Gilead Sciences, Inc. |
Cd73 inhibiting 2,4-dioxopyrimidine compounds
|
|
IL297522A
(en)
*
|
2020-05-06 |
2022-12-01 |
Amgen Inc |
Synthesis of vinylic intermediates
|
|
TWI827924B
(zh)
*
|
2020-05-06 |
2024-01-01 |
美商安進公司 |
大環Mcl-1抑制劑中間體的閉環合成
|
|
WO2021225823A1
(en)
*
|
2020-05-06 |
2021-11-11 |
Amgen Inc. |
Synthesis of vinylic protected alcohol intermediates
|
|
KR20230006544A
(ko)
|
2020-05-06 |
2023-01-10 |
암젠 인크 |
설폰아미드 중간체의 합성
|
|
TWI867217B
(zh)
*
|
2020-05-06 |
2024-12-21 |
美商安進公司 |
乙烯基環丁基中間體之合成
|
|
EP4165050A1
(en)
|
2020-06-10 |
2023-04-19 |
JANSSEN Pharmaceutica NV |
Macrocyclic 2-amino-3-fluoro-but-3-enamides as inhibitors of mcl-1
|
|
AU2021337589A1
(en)
*
|
2020-09-03 |
2023-03-30 |
Amgen Inc. |
Diol desymmetrization by nucleophilic aromatic substitution
|
|
JP2023541916A
(ja)
|
2020-09-15 |
2023-10-04 |
レボリューション メディシンズ インコーポレイテッド |
がんの治療における、ｒａｓ阻害剤としてのインドール誘導体
|
|
CN116457334A
(zh)
*
|
2020-11-19 |
2023-07-18 |
吉利德科学公司 |
用于制备大环mcl1抑制剂的方法和中间体
|
|
IL303079A
(en)
|
2020-11-24 |
2023-07-01 |
Novartis Ag |
Mcl-1 inhibitor antibody-drug conjugates and methods of use
|
|
MX2023006144A
(es)
*
|
2020-11-25 |
2023-06-06 |
Amgen Inc |
Alquenilacion enantioselectiva de aldehidos.
|
|
EP4255409A1
(en)
|
2020-12-07 |
2023-10-11 |
Cellestia Biotech AG |
Pharmaceutical combinations for treating cancer
|
|
EP4008324A1
(en)
|
2020-12-07 |
2022-06-08 |
Cellestia Biotech AG |
Combinations comprising an inhibitor of an anti-apoptotic protein, such as bcl-2, bcl-xl, bclw or mcl-1, and a notch signaling pathway inhibitor for treating cancer
|
|
ES3026771T3
(en)
|
2020-12-17 |
2025-06-12 |
Janssen Pharmaceutica Nv |
Macrocyclic branched 3-fluoro-but-3-enamides as inhibitors of mcl-1
|
|
TW202302145A
(zh)
|
2021-04-14 |
2023-01-16 |
美商基利科學股份有限公司 |
ＣＤ４７／ＳＩＲＰα結合及ＮＥＤＤ８活化酶Ｅ１調節次單元之共抑制以用於治療癌症
|
|
BR112023020877A2
(pt)
|
2021-04-26 |
2023-12-12 |
Janssen Pharmaceutica Nv |
2-aliltetra-hidrofuranos macrocíclicos como inibidores de mcl-1
|
|
CN118852330A
(zh)
|
2021-05-05 |
2024-10-29 |
锐新医药公司 |
用于治疗癌症的ras抑制剂
|
|
TW202313094A
(zh)
|
2021-05-18 |
2023-04-01 |
美商基利科學股份有限公司 |
使用ＦＬＴ３Ｌ—Ｆｃ融合蛋白之方法
|
|
CA3222269A1
(en)
|
2021-06-11 |
2022-12-15 |
Gilead Sciences, Inc. |
Combination mcl-1 inhibitors with anti-cancer agents
|
|
KR20240019330A
(ko)
|
2021-06-11 |
2024-02-14 |
길리애드 사이언시즈, 인코포레이티드 |
Mcl-1 저해제와 항체 약물 접합체의 조합
|
|
KR20240005901A
(ko)
|
2021-06-23 |
2024-01-12 |
길리애드 사이언시즈, 인코포레이티드 |
디아실글리세롤 키나제 조절 화합물
|
|
CN117355531A
(zh)
|
2021-06-23 |
2024-01-05 |
吉利德科学公司 |
二酰基甘油激酶调节化合物
|
|
US11999733B2
(en)
|
2021-06-23 |
2024-06-04 |
Gilead Sciences, Inc. |
Diacylglycerol kinase modulating compounds
|
|
CN117480155A
(zh)
|
2021-06-23 |
2024-01-30 |
吉利德科学公司 |
二酰基甘油激酶调节化合物
|
|
AR127308A1
(es)
|
2021-10-08 |
2024-01-10 |
Revolution Medicines Inc |
Inhibidores ras
|
|
US20230183216A1
(en)
|
2021-10-28 |
2023-06-15 |
Gilead Sciences, Inc. |
Pyridizin-3(2h)-one derivatives
|
|
CA3235986A1
(en)
|
2021-10-29 |
2023-05-04 |
Gilead Science, Inc. |
Cd73 compounds
|
|
EP4433484A1
(en)
|
2021-11-16 |
2024-09-25 |
JANSSEN Pharmaceutica NV |
Macrocyclic 2-amino-but-3-enamides as inhibitors of mcl-1
|
|
US20230203202A1
(en)
|
2021-12-08 |
2023-06-29 |
Dragonfly Therapeutics, Inc. |
Proteins binding nkg2d, cd16 and 5t4
|
|
US20230220106A1
(en)
|
2021-12-08 |
2023-07-13 |
Dragonfly Therapeutics, Inc. |
Antibodies targeting 5t4 and uses thereof
|
|
AU2022417491A1
(en)
|
2021-12-22 |
2024-05-23 |
Gilead Sciences, Inc. |
Ikaros zinc finger family degraders and uses thereof
|
|
JP2024546851A
(ja)
|
2021-12-22 |
2024-12-26 |
ギリアード サイエンシーズ， インコーポレイテッド |
Ｉｋａｒｏｓジンクフィンガーファミリー分解剤及びその使用
|
|
TW202340168A
(zh)
|
2022-01-28 |
2023-10-16 |
美商基利科學股份有限公司 |
Ｐａｒｐ７抑制劑
|
|
CR20240386A
(es)
|
2022-03-17 |
2024-10-24 |
Gilead Sciences Inc |
Degradadores de dedos de zinc de la familia ikaros y usos de estos
|
|
AU2023240346A1
(en)
|
2022-03-24 |
2024-09-19 |
Gilead Sciences, Inc. |
Combination therapy for treating trop-2 expressing cancers
|
|
TWI876305B
(zh)
|
2022-04-05 |
2025-03-11 |
美商基利科學股份有限公司 |
用於治療結腸直腸癌之組合療法
|
|
CA3254998A1
(en)
*
|
2022-04-05 |
2023-10-12 |
Amgen Inc. |
MCI-1 ANTAGONIST SALT AND SOLVATES FORMS
|
|
JP2025511331A
(ja)
*
|
2022-04-05 |
2025-04-15 |
アムジエン・インコーポレーテツド |
Ｍｃｉ－１アンタゴニストの非晶質及び結晶性形態
|
|
AU2023256670A1
(en)
|
2022-04-21 |
2024-10-17 |
Gilead Sciences, Inc. |
Kras g12d modulating compounds
|
|
CR20240553A
(es)
|
2022-05-20 |
2025-05-02 |
Servier Lab |
Conjugados de anticuerpo-fármaco de compuestos antineoplásicos y métodos de uso de los mismos
|
|
CA3260083A1
(en)
|
2022-07-01 |
2024-01-04 |
Gilead Sciences, Inc. |
CD73 COMPOUNDS
|
|
US20240091351A1
(en)
|
2022-09-21 |
2024-03-21 |
Gilead Sciences, Inc. |
FOCAL IONIZING RADIATION AND CD47/SIRPa DISRUPTION ANTICANCER COMBINATION THERAPY
|
|
AU2023409398A1
(en)
|
2022-12-22 |
2025-06-05 |
Gilead Sciences, Inc. |
Prmt5 inhibitors and uses thereof
|
|
AU2024252725A1
(en)
|
2023-04-11 |
2025-11-06 |
Gilead Sciences, Inc. |
Kras modulating compounds
|
|
AU2024259556A1
(en)
|
2023-04-21 |
2025-10-23 |
Gilead Sciences, Inc. |
Prmt5 inhibitors and uses thereof
|
|
WO2025006720A1
(en)
|
2023-06-30 |
2025-01-02 |
Gilead Sciences, Inc. |
Kras modulating compounds
|
|
TW202519517A
(zh)
|
2023-07-26 |
2025-05-16 |
美商基利科學股份有限公司 |
Ｐａｒｐ７抑制劑
|
|
WO2025024663A1
(en)
|
2023-07-26 |
2025-01-30 |
Gilead Sciences, Inc. |
Parp7 inhibitors
|
|
EP4516807A1
(en)
|
2023-08-28 |
2025-03-05 |
Consorcio Centro de Investigación Biomédica en Red |
Compositions for use in a method of providing improved hematopoietic stem cell engraftment
|
|
WO2025054530A1
(en)
|
2023-09-08 |
2025-03-13 |
Gilead Sciences, Inc. |
Pyrimidine-containing polycyclic derivatives as kras g12d modulating compounds
|
|
US20250101042A1
(en)
|
2023-09-08 |
2025-03-27 |
Gilead Sciences, Inc. |
Kras g12d modulating compounds
|
|
US20250154172A1
(en)
|
2023-11-03 |
2025-05-15 |
Gilead Sciences, Inc. |
Prmt5 inhibitors and uses thereof
|
|
TW202540185A
(zh)
|
2023-11-22 |
2025-10-16 |
法商施維雅藥廠 |
抗cd74抗體藥物結合物及其使用方法
|
|
TW202540186A
(zh)
|
2023-11-22 |
2025-10-16 |
瑞士商諾華公司 |
抗ｃｄ７抗體藥物結合物及其使用方法
|
|
WO2025126157A1
(en)
|
2023-12-15 |
2025-06-19 |
Advesya |
Anti-il-1rap binding domains and antibody-drug conjugates thereof
|
|
WO2025137640A1
(en)
|
2023-12-22 |
2025-06-26 |
Gilead Sciences, Inc. |
Azaspiro wrn inhibitors
|
|
WO2025245003A1
(en)
|
2024-05-21 |
2025-11-27 |
Gilead Sciences, Inc. |
Prmt5 inhibitors and uses thereof
|